DepressionNCT03679221
Motoric Cognitive Risk and Depression
An observational study of Depression and Geriatrics, run by Jewish General Hospital at 1 site in Canada.
Trial summary
The overall objective of the proposal is to examine the association between depression and the newly reported "motoric cognitive risk" (MCR) syndrome, which is a pre-dementia syndrome combining subjective cognitive complaint (i.e.; memory complaint) with objective slow gait speed, in the Canadian population, with the… Read more about this study
- Who is it for?
- Ages 45 to 85 years
- Conditions the study is for
- Depression, Geriatrics, Neurocognitive Disorders
- What is being tested?
- Data collection
- How many people
- 30,000 participants
- Where
- 1 siteCanada
- Study dates
- 24 Jul 2019to 1 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 85 years
- All sexes
- Adult, Older adult
Study population: Individuals eligible for this study will be the participants of the CLSA
Who may be able to join
- be participant of the comprehensive CLSA
Who cannot join
- dementia,
- mobility disability,
- no information about cognitive complaint,
- no measure of walking speed
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Association of Depression With "Motoric Cognitive Risk" Syndrome in the Canadian Population
The overall objective of the proposal is to examine the association between depression and the newly reported "motoric cognitive risk" (MCR) syndrome, which is a pre-dementia syndrome combining subjective cognitive complaint (i.e.; memory complaint) with objective slow gait speed, in the Canadian population, with the baseline assessment of the Canadian Longitudinal Study on Aging (CLSA).
The Canadian and global population are continuously aging. Moreover, the number of individuals affected by dementia is on the rise. One good predictor of dementia is Motoric Cognitive Risk (MCR) syndrome. MCR syndrome is a highly prevalent, newly defined syndrome that combines slow gait and subjective cognitive complaint. Depression is also highly prevalent in the older population and can affect both cognition and gait. Thus, an overlap between MCR and depression is possible. Yet few studies have examined the association between MCR and depression, thus emphasizing the importance of further investigating this association. This project encompasses determining the association of MCR syndrome with depression in the Canadian context as a step to better understand MCR syndrome in Canada.
Read the detailed description
Motoric Cognitive Risk syndrome (MCR) is a new clinical syndrome associating subjective cognitive complaint and objective slow gait speed with a high prevalence calculated around 10% in population aged 60 and above. MCR syndrome predicts mild and major neurocognitive disorders. MCR syndrome does not rely on a complex and time-consuming assessment, making it applicable to the aging population. Thus, MCR syndrome seems to be a good syndrome to identify individuals at risk of mild and major neurocognitive disorders in any type of healthcare setting.
Slow gait speed and cognitive complaint are unspecific symptoms that can apply to a wide variety of morbidities (i.e., having a disease or a symptom of disease), thus causing overlap with other syndromes which may influence the predictive value of MCR syndrome. One example of the same seen in previous literature is the overlap between MCR syndrome and Mild Cognitive Impairment (MCI) which is, a pre-dementia syndrome similar to MCR syndrome. Patients diagnosed with MCR syndrome can also be diagnosed with MCI, however, this is not always the case. It has been suggested that patients cumulating both syndromes could be more at risk of mild and major neurocognitive disorders. Similarly, anxiety, depressive symptomatology and/or clinical depression (ADSCD) may be associated with slow gait speed and cognitive complaint. Prevalence of ADSCD like MCR syndrome is high and estimated around 9%, with some age dependent variation: younger adults have a higher prevalence compared to older adults. Due to the high prevalence of both MCR syndrome and ADSCD, and in conjunction that subjective cognitive complaint (for MCR syndrome definition) has previously been extracted from an item of depressive questionnaires like Center for Epidemiologic Studies Depression scale (CESD) or Geriatric Depression Scale (GDS), there is a high probability of overlap between MCR syndrome and depression. As ADSCD is not a pre-dementia stage, an overlap between ADSCD and MCR syndrome can conversely to MCI syndrome result in a decreased risk for mild and major neurocognitive disorders.
Few studies have examined the association between ADSCD and MCR syndrome and reported diverging results. They found both significant and not significant associations between MCR syndrome and ADSCD. These mixed results may be explained by the definition used for ADSCD. For instance, studies have used depressive questionnaires or antidepressant use. Moreover, this divergence could also be related to the nature of the symptomology (e.g., anxiety or mood disorders), as well as age. Thus, it is important to examine the association between ADSCD and MCR syndrome taking in consideration these parameters.
The investigator has the opportunity with the baseline assessment of a large population-based prospective and observational study in Canada, known as the Canadian Longitudinal Study on Aging (CLSA) to better understand the parameters influencing the association between ADSCD and MCR syndrome.
- Conditions
- Depression, Geriatrics, Neurocognitive Disorders
- Being tested
- Data collection
- Medical subject headings
- Depression, Neurocognitive Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Data collectionOther
telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
| Study group | Role | What they receive |
|---|---|---|
| Group 45-54 years old | divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases Receives: Other: Data collection | |
| Group 54-64 years old | divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases Receives: Other: Data collection | |
| Group 65-74 years old | divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases Receives: Other: Data collection | |
| Group 75-85 years old | divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases Receives: Other: Data collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Subjective cognitive complaint
elicited from the 60-minute interview telephone questionnaire item Chronic Conditions Tracking (CTT_19 CCT_MEMPB_TRM) done in CLSA study
Measured: 1 hour
Secondary outcomes (1)
Slow gait speed
defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2018
- Study start24 Jul 2019
- Primary completion31 Oct 2024 (estimated)
- Study completion1 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DepressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 30,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jewish General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Olivier Beauchet, Jewish General Hospital
- Investigators
- Olivier Beauchet, MD, Principal investigator, Jewish General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03679221
- Sponsor's protocol ID
- 2019-1501
- Status last verified
- Feb 2024
- First submitted
- 18 Sep 2018
- Last updated
- 23 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Association of Depression With "Motoric Cognitive Risk" Syndrome in the Canadian Population
- ClinicalTrials.gov ID
- NCT03679221
- Acronym / sponsor ID
- 2019-1501
- Conditions
- Depression, Geriatrics, Neurocognitive Disorders
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 30,000 participants (estimated)
- Lead sponsor
- Jewish General HospitalUniversity, hospital or other
- Study start
- 24 Jul 2019 (actual)
- Primary completion
- 31 Oct 2024 (estimated)
- Study completion
- 1 Dec 2025 (estimated)
- First posted
- 20 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall objective of the proposal is to examine the association between depression and the newly reported "motoric cognitive risk" (MCR) syndrome, which is a pre-dementia syndrome combining subjective cognitive complaint (i.e.; memory complaint) with objective slow gait speed, in the Canadian population, with the baseline assessment of the Canadian Longitudinal Study on Aging (CLSA).
The Canadian and global population are continuously aging. Moreover, the number of individuals affected by dementia is on the rise. One good predictor of dementia is Motoric Cognitive Risk (MCR) syndrome. MCR syndrome is a highly prevalent, newly defined syndrome that combines slow gait and subjective cognitive complaint. Depression is also highly prevalent in the older population and can affect both cognition and gait. Thus, an overlap between MCR and depression is possible. Yet few studies have examined the association between MCR and depression, thus emphasizing the importance of further investigating this association. This project encompasses determining the association of MCR syndrome with depression in the Canadian context as a step to better understand MCR syndrome in Canada.
Detailed description
Motoric Cognitive Risk syndrome (MCR) is a new clinical syndrome associating subjective cognitive complaint and objective slow gait speed with a high prevalence calculated around 10% in population aged 60 and above. MCR syndrome predicts mild and major neurocognitive disorders. MCR syndrome does not rely on a complex and time-consuming assessment, making it applicable to the aging population. Thus, MCR syndrome seems to be a good syndrome to identify individuals at risk of mild and major neurocognitive disorders in any type of healthcare setting.
Slow gait speed and cognitive complaint are unspecific symptoms that can apply to a wide variety of morbidities (i.e., having a disease or a symptom of disease), thus causing overlap with other syndromes which may influence the predictive value of MCR syndrome. One example of the same seen in previous literature is the overlap between MCR syndrome and Mild Cognitive Impairment (MCI) which is, a pre-dementia syndrome similar to MCR syndrome. Patients diagnosed with MCR syndrome can also be diagnosed with MCI, however, this is not always the case. It has been suggested that patients cumulating both syndromes could be more at risk of mild and major neurocognitive disorders. Similarly, anxiety, depressive symptomatology and/or clinical depression (ADSCD) may be associated with slow gait speed and cognitive complaint. Prevalence of ADSCD like MCR syndrome is high and estimated around 9%, with some age dependent variation: younger adults have a higher prevalence compared to older adults. Due to the high prevalence of both MCR syndrome and ADSCD, and in conjunction that subjective cognitive complaint (for MCR syndrome definition) has previously been extracted from an item of depressive questionnaires like Center for Epidemiologic Studies Depression scale (CESD) or Geriatric Depression Scale (GDS), there is a high probability of overlap between MCR syndrome and depression. As ADSCD is not a pre-dementia stage, an overlap between ADSCD and MCR syndrome can conversely to MCI syndrome result in a decreased risk for mild and major neurocognitive disorders.
Few studies have examined the association between ADSCD and MCR syndrome and reported diverging results. They found both significant and not significant associations between MCR syndrome and ADSCD. These mixed results may be explained by the definition used for ADSCD. For instance, studies have used depressive questionnaires or antidepressant use. Moreover, this divergence could also be related to the nature of the symptomology (e.g., anxiety or mood disorders), as well as age. Thus, it is important to examine the association between ADSCD and MCR syndrome taking in consideration these parameters.
The investigator has the opportunity with the baseline assessment of a large population-based prospective and observational study in Canada, known as the Canadian Longitudinal Study on Aging (CLSA) to better understand the parameters influencing the association between ADSCD and MCR syndrome.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group 45-54 years old | – | Other: Data collectiondivided in two subgroups: individuals with and without cardio-vascular risk factors and diseases |
| Group 54-64 years old | – | Other: Data collectiondivided in two subgroups: individuals with and without cardio-vascular risk factors and diseases |
| Group 65-74 years old | – | Other: Data collectiondivided in two subgroups: individuals with and without cardio-vascular risk factors and diseases |
| Group 75-85 years old | – | Other: Data collectiondivided in two subgroups: individuals with and without cardio-vascular risk factors and diseases |
Who may qualify
- Ages
- 45 to 85 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Individuals eligible for this study will be the participants of the CLSA
Key inclusion criteria (1 listed)
- be participant of the comprehensive CLSA
Key exclusion criteria (4 listed)
- dementia,
- mobility disability,
- no information about cognitive complaint,
- no measure of walking speed
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Data collectiontelephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site | Other | Group 45-54 years old, Group 54-64 years old, Group 65-74 years old, Group 75-85 years old |
Primary outcome
Subjective cognitive complaint
Time frame: 1 hour
elicited from the 60-minute interview telephone questionnaire item Chronic Conditions Tracking (CTT_19 CCT_MEMPB_TRM) done in CLSA study
1 secondary outcome
Slow gait speed
Time frame: 1 day
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Depression
RecruitingPhase 1
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Depression, Major Depressive Disorder
Recruiting
To Improve Depressive Symptoms Using a Web-App
Depression
Active, not recruiting
Supporting Health in Veterans With Heart Failure
Heart Failure
Recruiting
Cancer Pain Management Using a Web-based Intervention
Cancer of Breast, Depressive Symptoms
Recruiting
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
Suicide, Bereavement
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Olivier Beauchet, MD principal investigator
Jewish General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Depression and Geriatrics, run by Jewish General Hospital at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Subjective cognitive complaint (time frame: 1 hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2024; AzTrials last refreshed its copy on 31 Oct 2026.